argenx (ARGX) Stock Forecast & Price Target

$640.52 -19.29 (-2.92%)

As of 01/17/2025 04:00 PM Eastern

argenx - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 22 Analyst Ratings

Sell
1

Hold
2

Buy
19

Based on 22 Wall Street analysts who have issued ratings for argenx in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 1 has given a sell rating, 2 have given a hold rating, 18 have given a buy rating, and 1 has given a strong buy rating for ARGX.

Consensus Price Target

$658.39
2.79% Upside

According to the 22 analysts' twelve-month price targets for argenx, the average price target is $658.39. The highest price target for ARGX is $725.00, while the lowest price target for ARGX is $500.00. The average price target represents a forecasted upside of 2.79% from the current price of $640.52.

Get the Latest News and Ratings for ARGX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for argenx and its competitors.

ARGX Analyst Ratings Over Time

Type	Current Forecast 1/21/24 to 1/20/25	1 Month Ago 12/22/23 to 12/21/24	3 Months Ago 10/23/23 to 10/22/24	1 Year Ago 1/21/23 to 1/21/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	18 Buy rating(s)	18 Buy rating(s)	17 Buy rating(s)	16 Buy rating(s)
Hold	2 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$658.39	$639.78	$550.44	$522.64
Forecasted Upside	2.79% Upside	2.56% Upside	-3.17% Downside	42.45% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ARGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ARGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

argenx Stock vs. The Competition

Type	argenx	Medical Companies	S&P 500
Consensus Rating Score	2.86	2.82	2.52
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	2.79% Upside	24,741.16% Upside	12.44% Upside
News Sentiment Rating	Neutral News See Recent ARGX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/17/2025	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Downgrade	Hold ➝ Sell
1/14/2025	HC Wainwright 2 of 5 stars	Douglas Tsao Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$670.00 ➝ $717.00	+6.76%
1/14/2025	Truist Financial 2 of 5 stars	Joon Lee Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$660.00 ➝ $700.00	+3.93%
1/14/2025	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jason Butler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Market Outperform ➝ Market Outperform	$606.00 ➝ $696.00	+3.82%
1/7/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$620.00 ➝ $725.00	+12.34%
12/19/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$639.00 ➝ $723.00	+15.90%
12/3/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$655.00	+4.97%
11/21/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$646.00 ➝ $675.00	+14.38%
11/21/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$675.00 ➝ $706.00	+19.29%
11/12/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$697.00	+18.35%
Get the Latest News and Ratings for ARGX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.
11/5/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Farmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$439.00 ➝ $715.00	+21.46%
11/4/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$640.00 ➝ $670.00	+12.61%
11/1/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Beatty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
11/1/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$585.00 ➝ $665.00	+10.12%
11/1/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$515.00 ➝ $650.00	+10.86%
11/1/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Minter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
10/17/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$512.00 ➝ $635.00	+16.89%
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy	$605.00	+16.23%
8/6/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Pitman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
6/24/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$535.00 ➝ $607.00	+40.57%
6/24/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$485.00 ➝ $500.00	+14.82%
5/28/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$515.00 ➝ $510.00	+39.29%
12/12/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$612.00 ➝ $641.00	+41.35%
10/2/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$605.00 ➝ $628.00	+29.56%
7/24/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$480.00 ➝ $570.00	+3.93%
6/15/2023	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sell
5/5/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
3/3/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$430.00 ➝ $435.00	+25.00%
3/3/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$430.00 ➝ $435.00	+26.07%
1/25/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$441.00 ➝ $458.00	+19.73%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:26 PM ET.

Should I Buy argenx Stock? ARGX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, January 19, 2025. Please send any questions or comments about these argenx pros and cons to contact@marketbeat.com.

argenx
Bull Case

Here are some ways that investors could benefit from investing in argenx SE:

argenx SE has received multiple upgrades from analysts, indicating strong confidence in its future performance. For instance, Guggenheim raised its price objective from $585.00 to $665.00, reflecting a bullish outlook.
The current stock price of argenx SE is $621.29, which is near its 12-month high of $644.97, suggesting strong market interest and potential for further growth.
Institutional ownership is significant, with 60.32% of the stock held by hedge funds and other institutional investors, which often indicates a strong vote of confidence in the company's prospects.
argenx SE is actively developing therapies for various autoimmune diseases, with its lead product candidate, efgartigimod, showing promise in treating conditions like myasthenia gravis and immune thrombocytopenia, which could lead to substantial revenue if successful.
Recent acquisitions by institutional investors, such as Central Pacific Bank Trust Division purchasing 1,000 shares valued at approximately $615,000, demonstrate growing interest and confidence in the company's future.

argenx
Bear Case

Investors should be bearish about investing in argenx SE for these reasons:

Despite the positive outlook, the stock has experienced volatility, with a 12-month low of $349.86, indicating potential risks associated with price fluctuations.
While there are many buy ratings, there are also three hold ratings, suggesting that some analysts are cautious about the stock's short-term performance.
The biotechnology sector can be highly unpredictable, with regulatory approvals and clinical trial results significantly impacting stock prices, which adds a layer of risk for investors.
Recent market conditions and economic factors could affect investor sentiment and stock performance, making it essential to consider broader market trends when investing.
Investors should be aware that the development of therapies can be a lengthy process, and delays or failures in clinical trials could adversely affect the company's stock value.

ARGX Forecast - Frequently Asked Questions

: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for argenx is $658.39, with a high forecast of $725.00 and a low forecast of $500.00.
: 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There is currently 1 sell rating, 2 hold ratings, 18 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARGX shares.
: According to analysts, argenx's stock has a predicted upside of 2.79% based on their 12-month stock forecasts.
: Over the previous 90 days, argenx's stock had 3 upgrades and 3 downgrades by analysts.
: argenx has been rated by research analysts at Baird R W, Deutsche Bank Aktiengesellschaft, Evercore ISI, Guggenheim, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Oppenheimer, Piper Sandler, Robert W. Baird, Scotiabank, Truist Financial, Wedbush, Wells Fargo & Company, William Blair, and Wolfe Research in the past 90 days.
: Analysts like argenx more than other "medical" companies. The consensus rating score for argenx is 2.86 while the average consensus rating score for "medical" companies is 2.82. Learn more on how ARGX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NASDAQ:ARGX) was last updated on 1/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

argenx (ARGX) Stock Forecast & Price Target